Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment

Glioma Clinical Trial

Official title:

Application of Cognitive Training Based on Remind Strategy in Glioma Patients With Cognitive Impairment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06327048
• Other study ID #: School of Nursing
• Status: Recruiting
• Phase: N/A
• Start date: March 6, 2024
• Est. completion date: December 1, 2024

Study information

• Verified date: March 2024
• Source: LanZhou University
• Contact: yuanyuan ma, Bachelor
• Phone: 0931-18809406184
• Email: 1657107645[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to form an interdisciplinary team to dynamically evaluate patient cognitive outcomes and develop an individualized cognitive training program for Chinese brain tumor patients

Description:

Adult patients diagnosed with glioma who meet the inclusion criteria will be enrolled in this study. Patients admitted to Neurosurgery Ward 1 and Ward 2 will be assigned to the intervention group, while those admitted to Neurosurgery Ward 3 and Ward 4 will serve as the control group. The intervention group will receive cognitive rehabilitation training based on the Remind strategy in addition to standard rehabilitation care, whereas the control group will receive only standard rehabilitation care. Assessment of patients' cognitive function, quality of life, psychological status, and the effectiveness of cognitive training intervention will be conducted on the first day of admission, one day before discharge, and at the end of the intervention period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: December 1, 2024
• Est. primary completion date: November 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Conforming to the diagnostic criteria outlined in the "Chinese Clinical Guidelines for Diagnosis and Treatment of Central Nervous System Gliomas (2015)" ;

2. Patients diagnosed with brain gliomas through histopathological and/or cytological examination;

3. MoCA (Montreal Cognitive Assessment) score = 26;

4. Karnofsky Performance Status (KPS) score = 60, with no history of past illnesses;

5. Age = 18 years;

6. Clear consciousness;

7. Willingness to participate and signed informed consent form.

Exclusion Criteria:

1. Diagnosed with neurological or psychiatric disorders within the past two years;

2. Impaired consciousness;

3. Accompanied by severe complications such as infections;

4. Nursing Delirium Screening Checklist (Nu-DESC) score = 2;

5. Patients with changes in condition or requiring repeat surgery;

6. Patients with multiple intracranial tumors;

7. Inability to effectively complete the questionnaire or withdrawal during the study.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Glioma

Intervention

Other:
• Individual cognitive rehabilitation training based on Remind strategy was given
This training educates and learns patients from the aspects of assessment of cognitive function and strategic compensation for the impact of cognitive impairment on patients, and then conducts attention, memory and executive function training and attention retraining based on patients' cognitive function to improve patients' cognitive function

Locations

Country	Name	City	State
China	Yuanyuanma	Lanzhou	Gansu

Sponsors (1)

Lead Sponsor	Collaborator
YuanYuan Ma

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montreal Cognitive Assessment(MoCA)	The Montreal Cognitive Assessment (MoCA) is commonly used to assess cognitive function, typically taking about 15 minutes to complete. It has a total score of 30 points, with a score of =26 considered normal. Lower scores indicate more severe cognitive impairment. MoCA is advantageous due to its ease of administration, short duration, and high reliability and validity.	The day after admission, 7 days after surgery, 2 months after surgery
Secondary	The European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ-C30)	The European Organization for Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ-C30) includes five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health and QoL scale, as well as individual items to assess other symptoms commonly experienced by cancer patients (such as dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and the perceived economic impact of the disease and treatment. All items are scored using a 4-point Likert scale (1: 'not at all'; to 4: 'very much'), except for two items in the global health/QoL scale which use a modified 7-point linear analog scale. Higher scores indicate poorer quality of life.	The day after admission, 7 days after surgery, 2 months after surgery
Secondary	The EORTC QLQ-Brain Neoplasms 20(EORTC QLQ-BN20)	The EORTC QLQ-Brain Neoplasms 20(EORTC QLQ-BN20) is a tool specifically designed to assess the quality of life of patients with brain tumors. The instrument consists of four multi-item scales covering: future uncertainty; visual disorders; motor dysfunction; communication deficit. Additionally, seven individual items assess headache, seizures, drowsiness, hair loss, itching, weakness of legs, and bladder control. All items and scores are evaluated on a scale of 0-100, with higher scores reflecting more severe symptoms.	The day after admission, 7 days after surgery, 2 months after surgery
Secondary	Self-Rating Anxiety Scale(SAS)	The Self-Rating Anxiety Scale (SAS) is used to assess the subjective feelings of anxiety patients. The scale consists of 20 items aimed at quantifying the severity of anxiety-related symptoms experienced by patients. It is divided into four levels on a Likert four-point scale: None or rarely, Sometimes, Often, and Always. Scores range from 20 to 80, with 20-44 considered normal, 45-59 indicating mild to moderate anxiety levels, 60-74 indicating severe anxiety levels, and extreme anxiety levels falling between 75 and 80.	The day after admission, 7 days after surgery, 2 months after surgery
Secondary	Self-Rating Depression Scale(SDS)	The Self-Rating Depression Scale (SDS) is used to assess an individual's subjective feelings of depression. The scale consists of 20 items rated on a Likert four-point scale: None or rarely, Sometimes, Often, and Always. Higher scores indicate higher levels of depression in the individual.	The day after admission, 7 days after surgery, 2 months after surgery
Secondary	Modified Barthel Index(MBI)	The Modified Barthel Index (MBI) is widely used in clinical practice to assess activities of daily living (ADL). It reflects patients' ability to perform self-care activities such as dressing, feeding, personal hygiene, as well as mobility activities such as sitting, standing, and walking. This scale is straightforward, easy to administer, and has good reliability and validity.	The day after admission, 7 days after surgery, 2 months after surgery